Introducing aiMOS: AI-Driven Media Optimization for Cell Therapy

This live interview is designed for cell therapy developers across PD, MSAT, CMC, and Manufacturing who are working to improve critical quality attributes (CQAs) while scaling toward clinical and commercial production. GeminiBio and Tolemy Bio will introduce aiMOS™, an AI-driven media optimization service that helps teams reduce variability, increase performance, and improve manufacturability without forcing a change to their base media. The core challenge is that today’s “one-size-fits-all” media and supplementation strategies often fail to account for differences in donor material, activation methods, culture platforms, and process conditions—leading to unpredictable outcomes and expensive troubleshooting cycles. aiMOS takes a different approach: it uses process data and, where available, multi-omics signals to identify the biological drivers of performance and recommend a process-specific supplement design and dosing strategy. The discussion will cover who aiMOS is for, how engagements work, and what “success” looks like in practice—from early development through scale-up.